STAT Expert Advantage
A Look at the Breast Cancer Landscape: An Expert’s Take on the Newly Approved Daiichi Sankyo Drug, ENHERTU, SGEN’s tucatinib, & the Role of IO therapy
A Look at the Breast Cancer Landscape: An Expert’s Take on the Newly Approved Daiichi Sankyo Drug, ENHERTU, SGEN’s tucatinib, & the Role of IO therapy
Walmart had grand ambitions, back in 2019, to grow a network of cheaper primary care clinics attached to its ubiquitous stores. Those ambitions are now…
This week on “The Readout LOUD” podcast: controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama.
Members of Congress appear likely to opt for a short-term extension of Medicare telehealth policies instead of permanent changes.
Amgen said that it will no longer develop an early-stage obesity pill, and will instead focus on an injectable candidate that’s seen as a potential…
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to…
The move by the California Supreme Court to review the case is seen as “very important,” according Evercore ISI analyst Umer Raffat.
UnitedHealth CEO Andrew Witty did not find a sympathetic audience when he testified before the House and Senate.
A USDA analysis shows the spread in cattle started from a single spillover event from birds in the Texas panhandle that may have happened in…
STAT Breakthrough Summit West is one-day event designed to break down silos across health and medicine by bringing together leaders, entrepreneurs, policymakers, patient advocates —…
Health economist Ben Handel dissects UnitedHealth CEO Andrew Witty’s Senate testimony on the the Change Healthcare cyberattack.